Paris France, May 22, 2013 -- MicroPort Scientific Corporation (00853.HK) participated at the European Association of Percutaneous Cardiovascular Interventions (EAPCI) which is a registered branch of the European Society of Cardiology (ESC). This year's EuroPCR meeting featured an all-time high turnout. Emerging fields in interventional cardiology research were center stage at the meeting, including various new data and educational sessions detailing the many facets of Drug-Eluting Stent with Bioabsorbable polymer and other percutaneous treatment of high blood pressure and transcatheter aortic valve replacement, among others.
In the morning of May 22, 2013, during the EuroPCR Conference "Innovative Stents and Scaffolds" Session, Mr. Bo Xu, professor from the Chinese National Center for Cardiovascular Disease Fuwai Hospital, presented the latest report on Firehawk® titled "Renaissance of DES, New Generation of Sirolimus-Eluting Stent: The Firehawk® Stent-MicroPort".
Firehawk® Rapamycin Targeted Eluting Coronary Stent ("Firehawk®") is the third generation drug-eluting stent system designed and manufactured exclusively by Shanghai MicroPort Medical (Group) Co., Ltd. The clinical results approved that Firehawk® is safe and effective. Furthermore it also indicated the feasibility and advantage of the "Targeted Release" feature on Firehawk®. Dr. Run-Lin Gao, C.K.Naber and P.W.Serruys presided over the meeting; G. Cassel, GB Danzi, C. Lotan attended the forum as special guests. The major discussion was about the past development and future trend in the research collaboration in Chinese cardiology field.
The TARGET Trial study compared the Rapamycin Targeted Eluting Coronary Stent (Firehawk®) with conventional everolimus-eluting stent with permanent polymer. The thesis titled "A randomized comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial" was published in the magazine. The overall TARGET study has a non-inferiority design with the primary endpoint of the in-stent late lumen loss at 12 months. Angiographic follow-up showed no major difference in the primary endpoint data and indicated same the feasibility, safety and efficacy between Firehawk® and Xience V.